Genelex executive to speak on 2015 SXSW discussion panel
Genelex will have a face at this year’s SXSW Interactive Festival, one of the world’s most well-known global technology conferences, in Austin, Texas, on March 16.
Kristine Ashcraft, Genelex’s Chief Operation Officer, will be part of a four-person panel discussion titled “Personalized Medicine: From a Vision Into a Plan”. The hour-long discussion will focus on how long it might take for the vision of personalized medicine to become a reality.
“They say it takes 17 years for medical research to make it to the patient; this is unacceptable, and we have the tools to shorten this timeline, especially in personalized medicine,” said Ashcraft, who joined Genelex in 2000.
“SXSW is known for attracting innovators that are pushing the envelope in many areas, and I am honored to speak and meet people that are interested in shortening the adoption curve.”
Ashcraft will join three other health care professionals in the field of personalized medicine on the discussion panel. The SXSW Interactive Festival is part of the larger, three-part SXSW conference, which also includes music and film festivals. Last year, more than 32,000 people attended the Interactive Conference alone.
Learn more about the conference and how to register here. Also, be sure to keep up with the personalized medicine discussion on Twitter by searching the hashtags #SXSW and #PersMed.
Talk of personalized medicine has received a boost recently after President Barack Obama’s State of the Union address, in which he called for a “precision medicine” initiative. The President made it clear that it is necessary and expedient to use modern technology to provide personalized treatment for all Americans, not just those suffering from complex diseases.
Genelex is proud to be leader in personalized medicine through its innovations in pharmacogenetic testing and analysis. Our YouScript Personalized Prescribing System pairs pharmacogenetic testing with the most comprehensive medication management software available.